Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Core Viewpoint - Keros Therapeutics reported significant financial improvements in Q1 2025, driven by a license agreement with Takeda Pharmaceuticals, and is advancing its clinical pipeline with promising results from its Phase 1 trial of KER-065, while preparing for a Phase 2 trial of cibotercept in 2026 [2][3][4]. Financial Performance - Keros reported a net income of $148.5 million for Q1 2025, a substantial increase of $191.6 million compared to a net loss of $43.1 million in Q1 2024, primarily due to revenue from a license agreement [3][12]. - Total revenue for Q1 2025 was $211.2 million, significantly up from $83,000 in Q1 2024, with license revenue contributing $195.4 million [11]. - Research and development expenses rose to $48.7 million in Q1 2025 from $38.3 million in Q1 2024, reflecting increased efforts in advancing the clinical pipeline [4]. - General and administrative expenses slightly increased to $10.5 million in Q1 2025 from $10.3 million in Q1 2024 [5]. Cash Position - As of March 31, 2025, Keros had cash and cash equivalents of $720.5 million, up from $559.9 million at the end of 2024, providing a strong financial position to fund operations through 2029 [6]. Clinical Development - Initial topline results from the Phase 1 clinical trial of KER-065 met key objectives, positioning the company to engage with regulators for a Phase 2 trial in Q1 2026 [2]. - Keros expects to report data from the Phase 2 TROPOS trial evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension in Q2 2025 [2]. Company Overview - Keros Therapeutics focuses on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family, with product candidates including cibotercept for pulmonary arterial hypertension and KER-065 for neuromuscular diseases [7].